Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06761911 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

StatusNot Yet Recruiting
PhasePhase 4
SponsorXiuhua Sun
Started2024-12-31
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 7, 2025 (before its estimated December 17, 2025 completion). Its status may not reflect the trial's current state.
The goal of this clinical trial is to explore the real-world Chinese relapsed/refractory patients to evaluate the efficacy and safety of BV monotherapy or combination therapy in CHL patients. The main questions it aims to answer are: To evaluate the efficacy and toxicity of BV-containing regimen in relapsed/refractory CHL patients in China, and to provide reference for the rational and safe use of BV in clinical practice.
Trial Details
NCT Number NCT06761911
Lead Sponsor Xiuhua Sun
Conditions Hodgkin Lymphoma (Category)
Enrollment 100 participants
Start Date 2024-12-31
Primary Completion 2025-12-17 (estimated)
Study Completion 2026-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-07